We’re improving your experience!

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02983604
Title GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer
Recruitment Terminated
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Gilead Sciences
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Stanford Women's Cancer Center Stanford California 94305 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Allina Health, Virginia Piper Cancer Institute Minneapolis Minnesota 55407 United States Details
The Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
Baylor University Medical Center Houston Texas 77030 United States Details
Medical Oncology Associates, PS (dba Summit Cancer Centers) Spokane Washington 99208 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field